Document is current

Article History

Received: 7 January 2026

Accepted: 10 April 2026

First Online: 6 May 2026

Declarations

:

: Participants were transparent about potential conflicts of interest throughout the process and did not receive any compensation regarding their specific relationships. Every effort was made to provide unbiased statements and mitigate any potential conflicts of interest (Supplemental Methods). Educational grants from industry were used to pay for accommodations, conference venue and administrative costs. No participants received payments for their participation. The sponsors of the conference were present to observe discussions. Sponsors did not participate in the processes and were not provided an advanced copy of the manuscript. The following are author-specific disclosures: AAA serves on the scientific advisory board for Seastar medica, Mallinckrodt and CSLVi and the institution receives funding from Mozarc Medical. GA received honoraria from the Werfen Group Research Meeting (2025) and serves on the ELSO Senior Advisory Committee. DA receives consulting fees from Seastar Medical and Nuwellis, has received payment for expert testimony from Williams and Williams, has 2 patents pending, is on the leadership team for the neonatal kidney collaborative, has stock options in Zorroflow, and the institution receives funding from Vantive. LA receives consulting fees from Boehringer Ingelheim and Medibeacon and received an American Society of Nephrology Travel Grant. SB receives grant funding from Vantive, consulting fees from Bioporto Calcimedica, Novartis and Vantive, has received honoraria from Vantive, and participated in DSMB for EPO-Trauma and Cinergy. BB has received payment for expert testimony from Marks Gray Law Firm, and Stoll Keenon Ogden Law Firm. DYF has no disclosures. KMG receives a grant from the Gerber foundation, is a consultant for Bioporto Diagnostics and SeaStar Medical, has received speaker honoraria from the University of West Virginia, and serves on the Board of Directors for the Neonatal Kidney Collaborative. SLG receives consulting fees from Vantive, Mozarc Medical, Bioporto Diagnostics, MediBeacon, SeaStar Medical, Otsuka, Calcimedica, has a patent with Medibeacon, serves on the DSMB for Entrada, Silver Creek Pharmaceuticals, has stock in Medibeacon and Calcimedica. SMG has no disclosures. GS is the president of the Canadian Cardiovascular Critical Care (CANCARE) Society and has disclosed a family with financial interests in Abbott Canada. PG has no disclosures. AK has no disclosures. KK receives honoraria from Vantive. ALF has no disclosures. MJC receives royalties from UptoDate Inc., has stock options in GE Healthcare. GM has no disclosures. DMM has no disclosures. RM receives consulting fees from AM Pharma, Baxter, Vantive, Fresenius, Idorsia, Bayer, Novartis, Renasym, Guard Pharmaceuticals, Vera, Alexion and Sphingotech, has received honoraria from Fresenius, and has participated in DSMB for Novartis and Guard Pharmaceuticals. SM receives funding from Gerber foundation, receives consulting fees from Mozarc Inc, and is a board member of the Neonatal Kidney Collaborative. TM receives consulting fees from Medtronic, honoraria from Vantive, and participates in a DSMB for SeaStar Medical Board. TM is an ELSO Board Member. MO receives grant funding from Baxter and Biomerieux, is the president elect of ESiCN and CoChair of the KDIGI AKI Guideline Committee. MP has a patent and is a past president of ELSO. TR receives grant funding from Jafron, Consulting fees from Eurofarma, George Clinical and Medcorp. He has received honoraria from Alexion, AstraZeneca, B. Braun, Baxter, bioMérieux, Boehringer Ingelheim, Eurofarma, George Clinical, Jafron, Medcorp, Nipro, Nova Biomedical, and Vantive, has received funding from Nipro, participated in a DSMB for Baxter. NR has no disclosures. CR has no disclosures. ES has no disclosures. DTS has received honoraria from Bioporto, is the president elect for the Neonatal Kidney Collaborative, Co-Chair of the IPNA Education Committee and Associate Editor for Pediatric Nephrology. DTS is also supported in part, by the Arkansas Children’s Research Institute and Arkansas Biosciences Institute. The remaining authors declare no competing interests.

: Source: Acute Disease Quality Initiative 2026; . Used with permission.